Kadayifci Abdurrahman, Merriman Raphael B, Bass Nathan M
Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143-0538, USA.
Clin Liver Dis. 2007 Feb;11(1):119-40, ix. doi: 10.1016/j.cld.2007.02.001.
There is no proven medical treatment of non-alcoholic steatohepatitis (NASH). Most prior therapeutic trials have had methodologic limitations. Insulin sensitizers are the more promising therapeutic candidates among categories that include antioxidants, lipid-lowering agents, and antiobesity drugs. The future will see the evaluation of novel agents and a comprehensive treatment strategy that addresses the risk factors for the metabolic syndrome. This article reviews the current status of medical management options for NASH.
目前尚无经证实的非酒精性脂肪性肝炎（NASH）医学治疗方法。大多数先前的治疗试验存在方法学上的局限性。在包括抗氧化剂、降脂药物和抗肥胖药物在内的各类药物中，胰岛素增敏剂是更有前景的治疗候选药物。未来将会对新型药物以及针对代谢综合征风险因素的综合治疗策略进行评估。本文综述了NASH医学管理方案的现状。
